{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-252984","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.894894+00:00","generated_at":"2026-06-10T02:27:28.374114+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Reneo Pharma announces last patient last visit in pivotal STRIDE study; topline data expected Dec 2023","bullets":["Last patient last visit completed in STRIDE study of mavodelpar for primary mitochondrial myopathies; topline data expected December 2023.","Over 85% of eligible patients enrolled in ongoing STRIDE AHEAD study.","Company to share data analysis with FDA in Q1 2024; NDA submission planned first half 2024.","STRIDE and STRIDE AHEAD studies to form basis of NDA submission to FDA and other regulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-252984","json":"https://secwatch.observer/filing/0001193125-23-252984.json","markdown":"https://secwatch.observer/filing/0001193125-23-252984.md","text":"https://secwatch.observer/filing/0001193125-23-252984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523252984/0001193125-23-252984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523252984/d535917d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:27:28.374114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}